Clinical Translation Of Self-Assembled Cancer Nanomedicines

Nanomedicines are emerging as effective approaches for developing new strategies against cancer. Nanomedicines can be designed for selectively delivering probes and anticancer agents to tumors for achieving improved diagnostic or therapeutic efficacy, while relieving potential side effects. In particular, the number of formulations based on self-assembled nanostructures under clinical evaluation is increasing due to their unique advantages for elegant and facile preparation, working at the biointerface and spatiotemporally controlling the function of drugs. Here, the current status of clinically used self-assembled nanomedicines is presented, and recent advances of candidates in clinical trials are reviewed. In addition, the challenges and future prospects of nanomedicines in the clinic are discussed.